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Abstract During angiogenesis, endothelial tip cells start
sprouting and express delta-like 4 (DLL4) downstream of
vascular endothelial growth factor (VEGF). DLL4 subse-
quently activates Notch in the adjacent stalk cells sup-
pressing sprouting. VEGF also activates A disintegrin and
metalloproteases (ADAMs) that induce Notch ectodomain
shedding. Although two major ADAMs, i.e. ADAM10 and
ADAM17, have been implicated in Notch-signalling acti-
vation, their apparent different roles in angiogenesis have
not been fully understood yet. The objective of this study
was to determine the roles of ADAM10 and ADAM17
activity in angiogenesis. In mouse retinas, ADAM10 or c-
secretase inhibition induced vascular sprouting and density
in vivo, whereas attenuation of both ADAM10 and
ADAM17 activity produced the opposite phenotype. Reti-
nal blood vessel analysis in ADAM17 hypomorphic mice
confirmed the requirement for ADAM17 activity in angi-
ogenesis. However, ADAM17 inhibition did not pheno-
copy blood vessel increase by Notch blockage. These
observations suggest that ADAM17 regulates other fun-
damental players during angiogenesis besides Notch,
which were not affected by ADAM10. By means of an
angiogenesis proteome assay, we found that ADAM17
inhibition induced the expression of a naturally occurring
inhibitor of angiogenesis Thrombospondin 1 (TSP1),
whereas ADAM10 inhibition did not. Accordingly,
ADAM17 overexpression downregulated TSP1 expression,
and the TSP1 inhibitor LSKL rescued angiogenesis in the
tube formation assay downstream of VEGF in the presence
of ADAM17 inhibition. Finally, genetic and pharmaco-
logical ADAM17 blockade resulted in increased TSP1
expression in mouse retina. Altogether, our results show
that ADAM10 and ADAM17 have opposite effects on
sprouting angiogenesis that may be unrelated to Notch
signalling and involves differentially expressed anti-
angiogenic proteins such as TSP1.
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Introduction
Over the last years, different studies have highlighted the
crucial function of the ADAM metalloproteinases in
physiological and pathological neovascularization [1–3].
During blood vessel formation, i.e. angiogenesis, a
subpopulation of ECs, called tip cells, start sprouting and
elongate filopodia in response to VEGF stimulation. The
proximal cells are stalk cells, which proliferate and form
the endothelial lining of the newly formed vessel structure.
The Notch ligand, DLL4, is expressed in tip cells and has
been reported to finely regulate this process by triggering
Notch1 activation in adjacent ECs and promoting their
differentiation into stalk cells, which are characterized by
low migration and filopodia capacity [4]. Notch signalling
is initiated by two distinct proteolytic events: the ADAM-
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mediated S2 cleavage generates an intermediate cleavage
product termed Notch extracellular truncation (NEXT),
which serves as substrate for the c-secretase and facilitates
the release of the signalling competent Notch intracellular
domain (NICD). Although two ADAMs, i.e. ADAM10 and
ADAM17, have been reported to cleave and activate Notch
receptors, it is still a matter of controversy that ADAM is
essential in this process. Adam17-deficient mice do not
show a ‘‘Notch phenotype’’ [5], whereas conditional inac-
tivation of ADAM10 in endothelial cells recapitulates the
phenotype observed by interfering with Notch signalling:
retinal vasculature exhibits increased branching and den-
sity [1]. In cell-based assays, ligand-induced Notch sig-
nalling requires ADAM10 and occurs at Val1711 S2
cleavage site [6]. Also in vivo in skin, lymphoid cells and
endothelial cells, ADAM10 deficiency affects canonical
NOTCH signalling [1, 7–9]. In contrast, ADAM17 seems
to be involved in ligand-independent Notch signalling [10],
albeit it is not sufficient in the absence of ADAM10 [11].
Moreover, conditional inactivation of ADAM17 in endo-
thelial cells did not affect normal developmental angio-
genesis, whereas it seemed to play a role during
pathological neovascularization in mice in vivo [3].
In the present study, we investigated the roles of
ADAM10 and ADAM17 in angiogenesis in gain of function
and loss of function experiments using genetic and phar-
macological approaches. Here, we show that concomitant
blockage of ADAM10 and ADAM17 resulted in a marked
decrease in vascular density and sprouting. In support of a
positive and specific role of ADAM17 in retinal angiogen-
esis, we showed that homozygous hypomorphic ADAM17ex/
ex mice, characterized by dramatic reduction of ADAM17
expression in all tissues, had a less developed and organized
vascular network. This phenotype strongly differs from the
one observed after ADAM10 pharmacological blockage
only, characterized by increased vascular density and
sprouting. Altogether, these results led us to speculate that
ADAM17 regulated other important players in angiogenesis
than Notch and different from ADAM10.
We show that ADAM17 inhibition induced the expres-
sion of the anti-angiogenic factor TSP1, whereas ADAM17
overexpression resulted in downregulation of TSP1 in ECs.
Addition of TSP1 inhibitors rescued the angiogenesis in the
presence of ADAM17 blockage downstream of VEGF. By
contrast, no effect on TSP1 was observed following
ADAM10 inhibition. In line with in vitro results, ADAM17
inhibition resulted in an increase in TSP1 when normalized
to the number of blood vessels in retinas isolated from
ADAM17ex/ex mice or WT pups injected with ADAM
inhibitors, as compared to Wt pups and/or Wt pups injected
with DSMO, respectively.
Altogether, these data highlight an opposite function of
the two major sheddases ADAM17 and ADAM10 during
sprouting angiogenesis. Whereas ADAM10 appears to be
the main metalloprotease to modulate Notch signalling and
to suppress angiogenesis, ADAM17 positively regulates
angiogenesis by regulating the crucial player TSP1.
Materials and methods
Animals
All animal studies were approved by the Animal Welfare
Committee of the University of Maastricht and Kiel Uni-
versity. Wild-type C57Bl6 mouse pups were used in our
experiments. In total, 100 mg/kg N-[N-(3,5-difluorophe-
nacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT)
(Sigma or Calbiochem, 565770) or 100 mg/kg of ADAM
inhibitors GI254023X (ADAM-10 inhibitors) or
GW413333X (ADAM10/ADAM17 inhibitor) were admin-
istered subcutaneously (injection volume 10 ll/g body
weight). Control mice were injected with vehicle only
(DMSO). Pups were injected daily for 48 h, starting at P5
and analysis on P7. Hypomorphic ADAM17 mice were
previously described in [12].
Reagents
Human cardiac microvascular endothelial cells (HCMvEC,
CC-2927) and human umbilical endothelial cells (HU-
VECs, CC-2517) (Lonza, Vervies, Belgium) were cultured
in EGM-2MV (CC-3162), with 5 % fetal bovine serum
(FBS; Lonza). Recombinant VEGFA165 (300-035) was
purchased from RELIATech GmbH (Brauschweig, Ger-
many); DLL4 (rDLL4, 1506-D4-050) was from R and D
System (Abingdon, Oxfordshire, UK); DAPT from Sigma-
Aldrich (D5942); TAPI0 (CAS 143457-40-3) was from
Calbiochem, Millipore (Billerica, MA, USA), LSKL
(60877) was from Anaspec (Liege, Belgium). ADAM
inhibitors GI254023X (ADAM10 inhibitors) and
GW413333X (ADAM10/ADAM17 inhibitor) were both
kindly provided by GlaxoSmithKline. Proteome Profiler
Human Angiogenesis Array Kit (ARY007) was from R and
D System (Abingdon, Oxfordshire, UK).
Cell culture and angiogenesis proteome assay
For inhibitor treatment, HCMvECs were incubated for 16 h
with GI254023X or GW413333X or TAPI0 prior to
VEGFA165. Cells were subcultured according to the man-
ufacturer’s protocol (Lonza), and viable cells count was
determined using trypan blue staining and the Countess
Automated cell Counter (Invitrogen). Cell culture super-
natant serum-free was collected and the expression levels
of 55 angiogenesis-associated proteins were analysed the
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Human Angiogenesis Antibody Array kit (R and D Sys-
tems, Proteome ProfilerTM) as recommended by the
manufacturer.
Plasmids and transfection
For exogenous Notch stimulation, HMvECs were stimu-
lated for 48 h with rDLL4 coated on immobilized DLL4 in
gelatin for 48 h as previously described [13] and then
subjected to transfection. pcDNA-encoding ADAM17 was
obtained from Addgene [14]. All transfection experiments
were carried out in triplicate. Transfections were performed
with lipofectamine LTX and PLUS reagent (Invitrogen,
15338-100). After 24 h of culture, mRNA was isolated and
QPCR analysis performed.
Western blotting
Proteins were isolated using Laemmli sample buffer
(Biorad) mixed with the 29 sample buffer (1:1) and
2-mercaptoethanol was added to cells. Samples were
heated at 95 C for 5 min, loaded on a 4–12 % gradient
Criterion XT Bis–Tris gel and were, subsequently, sub-
jected to electrophoresis in MOPS running buffer (BioRad)
at 200 V for 55 min. Proteins were transferred to a PVDF
membrane (BioRad) at 30 V overnight at 4 C using Tris-
glycin transfer buffer (Biorad). Non-specific binding of the
antibodies was blocked by incubating with 3 % milk
powder in TBS supplemented with Tween-20 (TBS-T) for
1 h. The membranes were exposed to anti-ADAM10 and
anti-ADAM17 Ab (Millipore), subsequently, incubated
with appropriated horseradish peroxidase labelled second-
ary antibody. As loading control, bactin expression was
detected using anti-bactin monoclonal antibody (Sigma).
The detection was performed by using SuperSignal West
Femto or Pico substrate (Pierce) and was visualized with
the ChemiDoc XRS System (BioRad).
RNA isolation and RT-qPCR
After each experiment, RNA was isolated by using RNeasy
micro kit Qiagen (Qiagen, GmbH, Hilden, Germany). A total
of 100 ng RNA per sample was subjected to real-time
reverse transcription polymerase chain reaction (RT-PCR)
by using a BIORAD MiQ5 (Biorad, Veenendaal, The
Netherlands) with Quanta reagents (VWR international BV,
Amsterdam, the Netherlands) and primer concentration of
10 lM according to Van den Akker et al. [15]. PCR Primers
used were: human b-ACTIN-sense: 50-ATCCTCACCCTG
AAGTACCC-30, b-ACTIN-antisense: 50-CACGCAGCTC
ATTGTAGAAG-30; GADPH-sense: 50-GCCTCAAGATC
ATCAGCAAT-30 GADPH-antisense: 50-GGACTGTGGTC
ATGAGTCCT-30; DLL4-sense: 50-ACAACTTGTCGGAC
TTCCAG-30, DLL4-antisense: 50-CAGCTCCTTCTTCTG
GTTTG-30; HES-1-sense: 50-CCAAAGACAGCATCTGA
GCA-30, HES-1-antisense: 50-GCCGCGAGCTATCTTTCT
T-30; TSP1-sense: 50-CTGACTCAGGACCCATCTAT-3;
TSP1-antisense: 50-CCAGTCTTTGTCTCCCTTTC-30. Prim-
ers were designed with oligoperfectTM Designer (Invitrogen),
Primer3 and Mfold (http://www.idtdna.com/scitools/Applica
tion/mfold/) and were synthesized by Eurogentec (Seraing,
Belgium).
Matrigel assay
For Matrigel network assay, 15 l Slide Angiogenesis (Ibidi,
81506) were filled with 10 ll Reducing Growth Factor
Matrigel (BD Bioscience) were incubated in appropriate
growth medium with or without 10 ng/ml of VEGFA, LSKL
and 5 lM GI, GW or TAPI0. After 30 min, 10,000 HUVECs
were seeded. The following day cells images were taken with
EVOS fluorescent microscope and analysed by ImageJ
(Version 1.48b NIH public domain software. The number of
junctions was quantified by ‘‘Angiogenesis Analyzer’’ by
Gilles Carpentier (http://image.bio.methods.free.fr/ImageJ/
?Angiogenesis-Analyzer-for-ImageJ).
Retina isolation and immunohistochemistry
Retinas were isolated and stained as previously described
in [16]. Isolectin GS-IB4 (20 lg/ml, I21411, Invitrogen)
was used to stain blood vessels. TSP1 was stained with a
rabbit polyclonal antibody (Abcam ab85762, 5 lg/ml) and
secondary antibody Alexa Donkey Antibody 594 (R37119,
Invitrogen). Photos were taken using a Leica DFC350 FX
digital camera or Leica TCS SPE confocal. Quantifications
vessel branch points: To assess the density of the vascular
plexus, we quantified the number of branch points per area
200 9 200 lM fields, micrographs taken with 20 9 0.75
NA lens, 24–32 fields, 6–8 retinas for Ctrl-, DAPT-, GI-
and GW-treated groups or Wt, Wt/ex and ex/ex groups. To
define vascular density, percentage of Isolectin B4-positive
vessels areas was measured and calculated using ImageJ.
Relative TSP1 immunofluorescent intensity was measured
on four micrographs taken with 40 9 1.25 NA lens per
retina. A total of four retinas per group were analysed.
TSP1 intensity values were normalized to vascular density.
Statistical analysis
Statistical significance was determined by applying one-
way ANOVA/Tukey’s or Student’s t (SigmaStat Software,
San Jose, USA) tests. Values are expressed as mean ± SD
of 3 in vitro experiments or 4 or 6–8 retinas per group.
P values of \0.05 were considered significant.
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Results
ADAM17 and ADAM10 inhibition produces
an opposite phenotypes in mouse retinal vasculature
In order to assess the effect of ADAM10 and ADAM17
inhibition on sprouting angiogenesis, we injected early
postnatal (P5) wild-type mice with GI a potent ADAM10
inhibitors, GW a dual ADAM 10/17 inhibitor or the c-
secretase inhibitor DAPT for 48 h. Whole-mount analysis
of the retinal vasculature after isolectin B4 staining
revealed that the inhibition of ADAM10 alone with GI
(Fig. 1a III, VII, XI; Fig. 1b, c) increased vessel sprouting
and density compared with controls (Fig. 1a I, V, IX;
Fig. 1b, c), essentially phenocopying pharmacological
inhibition of Notch activation with the c-secretase inhib-
itor DAPT (Fig. 1a II, VI, X; Fig. 1b, c). Conversely,
combined ADAM10 and ADAM17 inhibition with GW
resulted in reduced vascular density and sprouting angi-
ogenesis (Fig. 1a IV, VIII, XII; Fig. 1b, c) (n = 6,
P \ 0.001). These results support recent observations that
ADAM10 mediate ligand-induced Notch processing
in vitro and in vivo [6, 7, 10], recapitulating the pheno-
type observed following Notch inhibition with DAPT.
ADAM17 on the other hand seems to regulate other
fundamental function of endothelial cells independent of
Notch signalling [17], which are essential for
angiogenesis.
Fig. 1 ADAM10 and ADAM17 differentially affect angiogenesis.
a IsolectinB4 staining of retinas from 7 day-old pups injected and
treated with DAPT, GI and GW and DMSO (control; Ctrl) for 48 h
(magnification 95 (I–IV), 910 (V–VIII) and 940 (IX–XII),
respectively). b, c Quantification shows that DAPT and GI treatment
both resulted in a significant increase (*), whereas GW resulted in a
significant decrease (**), of vascular density and branching points per
field compared to Ctrl
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Genetic inactivation of ADAM17 in hypomorphic mice
(ADAM17ex/ex) affects retinal vasculature
To confirm the non-redundant role of ADAM17 in blood
vessel formation, we assessed angiogenesis in retinas
obtained from P7 ADAM17ex/ex hypomorphic mice witch
display a dramatically reduced ADAM17 expression in all
tissues [12]. As shown in Fig. 2a–c vascular density and
sprouting were markedly decreased in ADAM17ex/ex
homozygous mice compared with the wild-type (Wt) and
heterozygous (Wt/ex) animals used as control groups
(n = 6, P \ 0.001. Also in ADAM17ex/ex homozygous
mice, retinal vasculature appeared highly disorganized as
compared to Wt and Wt/ex mice (Fig. 2a).
ADAM17 regulates TSP1 expression in ECs
The reduction in blood vessel density in ADAM17ex/ex and
following combined ADAM10 and ADAM17 inhibition
compared to ADAM10 inhibition only, suggested an oppo-
site role for ADAM10 and ADAM17 during angiogenesis.
Whereas ADAM10 blockage recapitulated the typical Notch
phenotype in endothelium, ADAM17 seemed to modulate
angiogenesis in a Notch signalling-independent manner.
In order to identify the specific ADAM17 targets, we
performed an angiogenic proteome assay following stim-
ulation of ECs with VEGF and ADAM10 (GI) or
ADAM10/ADAM17 (GW) or ADAM17 inhibitor (TAPI-
0). By screening 55 angiogenesis proteins, we found that
ADAM17 inhibition upregulated a well-known natural
inhibitor of angiogenesis, thrombospondin-1, TSP1
(Fig. 3a), whereas ADAM10 inhibition did not display any
effect on the expression of TSP1 (Fig. 3a).
In line with these results, ectopic ADAM17 expression,
in HMvECs downregulated TSP1 expression (Fig. 3b),
whereas transfection of ADAM10 did not show any effect
(Fig. 3b).
TSP1 inhibitors rescued angiogenesis inhibition
by knockdown of ADAM17 downstream of VEGF
To further determine the inhibitory potential of TSP1 on
angiogenesis downstream of ADAM17, we stimulated
HUVECs with VEGF and ADAM10 or ADAM17 inhibitors
in the presence or absence of TSP1 inhibitor LSKL. In line
with the in vivo data, ADAM10/ADAM17 or ADAM17
inhibition reduced, whereas ADAM10 alone augmented,
VEGF-induced ECs tube formation on matrigel (Fig. 4a, b).
Fig. 2 Reduced angiogenesis in ADAM17 ex/ex hypomorphic mice.
a Isolectin-B4 staining of retinas from 7 day-old Wt, Wt/ADAM17 ex
and ADAM17 ex/ex hypomorphic mice (magnification 5X (I–III),
respectively). Retinas isolated from hypomorphic ADAM17 (ex/ex)
animals showed less vascular density and more disorganized vascular
network compared to Wt and heterozygous Wt/ex corresponding
animals. b, c Quantification analysis shows that ex/ex mice retinas had
higher vascular density and branching points (*) per field compared to
Ctrl
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TSP1 inhibitor LSKL administration neutralized the anti-
angiogenic effect of ADAM17 blockage by GW or TAPI0
administration, downstream of VEGF. Altogether, these data
indicate that ADAM17 positively regulates angiogenesis by
reducing TSP1 expression.
ADAM17 blockage resulted in increase TSP1 in mouse
retinas
In order to assess the effect of ADAM17 on TSP1
expression in vivo, retinas from ADAM17 inhibitor GW-
injected mice and ADAM17ex/ex hypomorphic were isolated
and subjected to immunofluorescent staining for TSP1. We
found that TSP1, besides being expressed in retinal vas-
culature, was also localized in the proximity of endothelial
cells in the vascular regions. These observations are con-
sistent with previous studies showing that TSP1 acts as a
secreted angiocrine suppressor, which is promptly degra-
ded [18, 19]. Here, we show that following pharmacolog-
ical and/or genetic inactivation of ADAM17, TSP1
expression is increased when normalized to the vascular
area, as compared to Wt pups and/or Wt pups injected with
DSMO, respectively (Fig. 5).
Discussion
In the present study, we report on opposite angiogenic
phenotypes observed following ADAM10 inhibition and
loss of ADAM17 function. While inhibition of ADAM10
activity mimicked loss of Notch signalling using c-secre-
tase inhibitors and induced vessel sprouting and density,
pharmacological and genetic inhibition of ADAM17
resulted in the opposite phenotype in mouse retinal blood
vessels (Fig. 1). The data, while supporting the general
importance of ADAM10-induced Notch signalling [7],
highlight a new role for ADAM17 during retinal sprouting
angiogenesis.
In support of a specific role of ADAM17 in retinal
angiogenesis, we showed that homozygous hypomorphic
ADAM17ex/ex mice had a less developed and organized
vascular network. These results differ from a recent study,
which provided evidence that ADAM17 from endothelial
cells is not involved in normal developmental angiogenesis
or vascular homeostasis [3]. Conditional ADAM17 dele-
tion on endothelial cells did in fact not result in a particular
retinal vasculature phenotype. For our experiments, we
used hypomorphic mice that show a 95 % decrease in
ADAM17 expression in all tissues. It is thus possible that
other sources of ADAM17 besides endothelial cells are
responsible for its activity during developmental angio-
genesis or may rescue lack of endothelial ADAM17
activity. In accordance with our data in hypomorphic mice,
ADAM17 inhibition prevented VEGF-induced ECs pro-
liferation and tube-like formation.
Also in line with our results, Lucitti et al. [17], by the
use of conditional and global knockouts, demonstrated that
ADAM10 and ADAM17 display opposite roles during pial
collateral formation based on mechanisms associated with
sprouting/branching. ADAM17 promoted collateral for-
mation, whereas ADAM10 suppressed excessive tip cell
formation. Similar to EC-specific ADAM10 knockdown
[1], pharmacological inhibition of c-secretase activity
resulted in increased collaterogenesis.
Fig. 3 ADAM17 modulates TSP1 expression. a Human angiogenesis
array was screened using conditioned media from HMvECs treated
with or without VEGFA ? GI, GW or TAPI0 and were compared
with control (Ctrl, set at 1). Inhibition of ADAM17 with GW or
TAPI0 increased TSP1 protein level. b Western blot analysis of
protein extracts from HMvECs transiently transfected with ADAM10
or Mock pcDNA (left panel) and ADAM17 or Mock pcDNA (right
panel). Results are from one representative experiment. Overexpres-
sion of ADAM17 in HMvECs resulted in significant TSP1 mRNA
downregulation, whereas ADAM10 overexpression did not show any
effect
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It appeared from these results that ADAM17 differs from
ADAM10 by mainly regulating angiogenesis in a Notch-
independent way. Therefore, we investigated what other
molecular mechanisms are affected by ADAM17 during the
process of angiogenesis. By means of an angiogenic pro-
teome assay, we demonstrated that ADAM17 inhibition
was able to upregulate a well-known natural inhibitor of
angiogenesis, TSP1. In support of this observation, over-
expression of ADAM17 resulted in downregulation of
TSP1 expression in ECs. Consistently, pharmacological and
genetic inhibition of ADAM17, resulted in a relative
upregulation of TSP1 expression when normalized to vas-
cular area. Recently, Ghajar et al. [19] have demonstrated
that TSP1 is highly expressed in stable vasculature in dor-
mant tumour niches. On the other hand, the tumour-sup-
pressive nature of microvascular endothelium is lost at the
sprouting endothelial cells, which are characterized by
reduced TSP1 expression. Altogether, these observations
Fig. 4 LSKL counteracts the
negative effect of ADAM17
inhibition on tube formation.
a HUVECs tube formation
(n = 3) was significantly
increased following VEGFA or
VEGFA ? GI treatment (II, III)
as compared to control (I). By
contrast, ADAM17 inhibitor
GW or TAPI0 (IV, V) reduced
tube formation despite VEGFA
administration. Addition of
10 ng/ml TSP1 inhibitor LSKL
neutralized the anti-angiogenic
effect of ADAM17 blockage
(VI, VII). Each photograph
shows a representative well of
triplicate wells set-up for each
group. b Tube formation was
quantified by assessing the
number of junctions counted for
each group (*) significantly
different from Ctrl
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are consistent with our observations that ADAM17 nega-
tively regulates TSP1 and that the decrease in blood vessel
density and sprouting following ADAM17 inhibition is
likely due to an upregulation of TSP1. Accordingly, TSP1
inhibition rescued angiogenesis in the tube formation assay
in the presence of ADAM17 blockage downstream of
VEGFA.
Due to its crucial role in angiogenesis and its high
expression level in tumour stroma and vasculature, DLL4
Notch signalling has been considered a suitable therapeutic
target to block angiogenesis in cancer [20–22]. Paradoxi-
cally, despite an increased vessel number by DLL4
blockade, such vessels were not functional and poorly
perfused, resulting in tumour size decrease [23, 24]. For
this reason, anti-DLL4 antibodies have recently entered
clinical trials [23]; however, the toxic side effects after
Notch inhibition are still poorly understood. DLL4-block-
ing therapies present a number of serious limitations.
Chronic DLL4 blockade has been reported to abnormally
activate ECs, disrupt normal organ homeostasis and pro-
duce significant pathology in multiple organs, inducing
vascular neoplasms [25]. Intriguingly, Notch blockade
results in an increase in tip cell number. Recently, it has
been shown that tumour growth accelerates around tip
cells, which release growth factors activating dormant
tumour cells [19]. Moreover, following Notch blockade
blood vessels become leaky, creating a hostile tumour
environment. Long-term vessel disruption causes hypoxia
Fig. 5 TSP1 expression was increased in mouse retina blood vessels
following ADAM17 blockage. a IsolectinB4 (green) and TSP1 (red)
of retinas from 7 day-old pups injected GW and DMSO (control; Ctrl)
for 48 h (magnification 940). b Quantification shows that GW
treatment resulted in a significant increase (*P \ 0.05) of TSP1
expression when normalized to vascular area compared with Ctrl.
c IsolectinB4 (green), TSP1 (red) of retinas from 7 day-old pups from
Wt and ADAM17 ex/ex hypomorphic mice (magnification 940).
d Quantification shows that ADAM17 ex/ex hypomorphic mice have a
significantly increased (*P\0.05) TSP1 expression when normalized
to vascular area compared to Wt mice. (Color figure online)
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in the tumour, which may trigger a pro-angiogenic
response by the release of vascular endothelial growth
factors and activation of metalloproteases.
Therefore, research is now focusing on the identification
of new molecular targets, besides Notch, in order to find an
effective strategy to prevent blood vessel formation in solid
cancer.
Recent studies have highlighted the positive role of
ADAM17 in pathological angiogenesis [3, 26], suggesting
it as a potential therapeutic target. Specific ADAM17
inhibition could provide a new tool to achieve blood vessel
inhibition in tumours.
In this study, we showed that ADAM17 and ADAM10
display opposite effects on angiogenesis. Whereas ADAM10
negatively regulates angiogenesis, ADAM17 has a positive
role in this process by inhibiting the expression of the anti-
angiogenic factor TSP1. Noteworthy, inhibition of both
ADAM10 and ADAM17 prevented a dramatic increase in
blood vessel density and fusion observed after administra-
tion of the Notch inhibitor DAPT or an ADAM10 inhibitor
alone. Further studies are needed to investigate whether
inhibition of concomitant Notch and ADAM17 could pro-
vide a new potentially applicable clinical tool to prevent
excessive non-functional angiogenesis in solid tumours
characterized by highly active Notch signalling.
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